<MedlineCitation Status="Completed">
<MedlineID>10011602</MedlineID>
<PMID>570437</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2001</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0365-9615</ISSN>
<JournalIssue>
<Volume>87</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>[Preliminary lymphocyte activation by a mitogen as a condition for demonstrating the ability of the Fab-fragment of normal IgG to inhibit lymphocyte transformation]</ArticleTitle>
<Pagination>
<MedlinePgn>182-4</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Peculiarities attending inhibition of the PHA-induced blast-cell transformation of human lymphocytes by F(ab')2 fragment of rabbit IgG were studied. It was shown that the fragment did not affect the intensity of blast-cell transformation if the lymphocytes were preliminarily incubated with the fragment for 24 h at 37 degrees or 4 degrees C and then transferred to the fresh medium containing PHA. However, if the fragment was added to the cells 24 or 48 h following PHA it produced a significant inhibition of the blast-cell transformation. These data may indicate that F(ab')2 fragment interferes with the lymphocyte transformation only when the cells are already activated with PHA.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Margulis</LastName>
<ForeName>G U</ForeName>
<Initials>GU</Initials>
</Author>
<Author>
<LastName>Baranova</LastName>
<ForeName>F S</ForeName>
<Initials>FS</Initials>
</Author>
<Author>
<LastName>Kul'berg</LastName>
<ForeName>A Ia</ForeName>
<Initials>AIa</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Predvaritel'naia aktivatsiia limfotsitov mitogenom kak uslovie dlia proiavleniia sposobnosti Fab-fragmentov normal'nogo IgG ingibirovat' transformatsiiu limfotsitov.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>USSR</Country>
<MedlineTA>Biull Eksp Biol Med</MedlineTA>
<NlmUniqueID>0370627</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Binding Sites, Antibody</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Immunoglobulins, Fab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Phytohemagglutinins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Binding Sites, Antibody</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>English Abstract</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Immunoglobulin G</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Immunoglobulins, Fab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Lymphocyte Transformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Phytohemagglutinins</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Rabbits</DescriptorName>
<QualifierName>immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
